1Upton, GV. Therapeutic considerations in the management of the climacteric. J Reprod Med 1984; 29: 71–80.
2Session, DR, Kelly, AC, Jewelewicz, R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril 1993; 59: 277–84.
3Mishell, DR. Estrogen replacement therapy: an overview. Am J Obstet Gynecol 1989; 161: 1825–27.
4Cauley, JA, Cummings, SR, Black, DM, Mascioli, SR, Seeley, DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163: 1338–44.
5Paganini-Hill, A, Henderson, VW. Estrogen replacement therapy and the risk of Alzheimer's disease. Arch Intern Med 1996; 156: 2213–17.
6Utian, WG, Schiff, I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1: 39.
7Ravnikar, VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332.
8Hemminiki, E, Brambilla, DJ, McKinlay, SM, Posner, JG. Use of estrogens among middle aged Massachusetts women. DICP 1991; 25: 418–23.
9Wren, BG, Brown, L. Compliance with hormonal replacement therapy. Maturitas 1991; 13: 17–21.
10Flowers, CE, Wilborn, WH, Hyde, BM. Mechanisms of uterine bleeding in postmenopausal women receiving estrogen alone or with a progestin. Obstet Gynecol 1985; 61: 135–43.
11Marslew, U, Riis, BJ, Christiansen, C. Progestogens: therapeutic and adverse effects in early postmenopausal women. Maturitas 1991; 13: 7–16.
12Whitehead, MI, Hillard, TC, Crook, D. The role and use of progestogens. Obstet Gynecol 1990; 75: 559–76.
13Nachtigall, LE. Enhancing patient compliance with hormonal replacement therapy at menopause. Obstet Gynecol 1990; 4(S): 77s–80s.
14March, MS, Whitehead, MI. The practicalities of hormone replacement. Balliéres Clin Endocrinol Metab 1993; 7: 183–202.
15Birkenfeld, A, Kase, NG. Menopause medicine: current treatment options and trends. Compr Ther 1991; 17: 36–45.
16Lobo, RA, Pickar, JH, Wild, R, Walsch, B. Hirvonen for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987–95.
17Grey, AB, Cundy, TF, Reid, IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 1994; 40: 671.
18Staland, B. Continuous treatment with a combination of estrogen and gestagen. A way of avoiding endometrial stimulation. Acta Obstet Gynecol Scand Suppl 1985; 130: 29.
19Magos, AL, Brincat, M, Studd, JWW et al. Amenorrhea and endometrial atrophy with continuous oral estrogen and progesterone therapy in postmenopausal women. Obstet Gynecol 1985; 65: 496.
20Sporrong, T, Hellgren, M, Samsioe, G et al. Comparison of four continuously administered progestogen plus estradiol combinations for climacteric complaints. Br J Obstet Gynecol 1988; 95: 1042.
21Weinstein, L, Bewtra, C, Gallagher, JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162: 153.
22Williams, SR, Frenchek, B, Spsroff, L et al. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol 1990; 162: 438.
23Hillard, TC, Siddle, NC, Whitehead, MI et al. Continuous combined conjugated equine estrogenprogestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histological diagnosis. Am J Obstet Gynecol 1992; 167: 1.
24Obel, EB, Munk-Jensen, N, Svenstrup, B et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16: 13.
25Rauch, U, Taubert, HD. Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable doses. A preliminary study. Maturitas 1993; 17: 123.
26MacLennan, AH, MacLennan, A, Wenzel, S et al. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomized trial. Med J Aust 1993; 159: 102.
27Marsh, MS, Crook, D, Whitcroft, SIJ et al. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994; 83: 19.
28Archer, DF, Pickar, JH, Bottiglioni, F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686.
29Munk-Jensen, N, Ulrich, LG, Obel, EB et al. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoproteins in a two year placebo controlled trial. Am J Obstet Gynecol 1994; 171: 132.
30Voetberg, GA, Netelenbos, JC, Kenemans, P et al. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994; 79: 1465.
31Spaulding, CB. Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement. Fertil Steril 1994; 62: 1181.
32The Postmenopausal Estrogen/Progestin Interventions Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199.
33Clisham, PR, deZiegler, D, Lozano, K et al. Comparison of sequential versus continuous estrogen and progestin replacement therapy in post-menopausal women. Obstet Gynecol 1991; 77: 241.
34Luciano, AA, DeSouza, MJ, Roy, MP et al. Evaluation of low dose estrogen and progestin therapy in post-menopausal women. J Reprod Med 1993; 38: 207.
35Weinstein, L. Efficacy of a continuous estrogenprogestin regimen in the menopausal patient. Obstet Gynecol 1987; 69: 929.
36Kable, WT, Gallagher, JC, Nachtigal, L et al. Lipid changes after hormone replacement therapy for menopause. J Reprod Med 1990; 35: 512.
37Nang, SL, Webster, MA, Wren, BG. Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy. A study of bleeding pattern, endometrial response, serum lipid and bone density changes. Aust NZ J Obstet Gynaecol 1995; 35: 92.
38Yancey, MK, Stone, IK, Hannan, CJ. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertil Steril 1990; 54: 778.
39Andersson, K, Mattsson, L, Rybo, G et al. Intrauterine release of levonorgestrel. A new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963.
40Raudaskoski, TH, Lahti, El, Kauppila, AJ et al. Transdermal estrogen with a levonorgestrelreleasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114.
41Marslew, U, Riis, BJ, Christiansen, C. Bleeding patterns during continuous combined estrogen progestogen therapy. Am J Obstet Gynecol 1991; 164: 1163.
42Keller, PJ, Holtz, E, Imthrun, B. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. Maturitas 1992; 15: 195.
43Marslew, U, Overgaard, K, Riis, BJ et al. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: longterm effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992; 79: 202.
44Hargrove, JT, Maxson, WS, Wentz, AL et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73: 606.
45Prough, SG, Aksel, S, Wiebe, RH et al. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987; 157: 1449.
46Luciano, AA, Turksoy, RN, Carleo, J et al. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet Gynecol 1988; 71: 39.
47Leather, AT, Savvas, M, Studd, JWW. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1088.
48Holst, J, Cajander, S, von Schoultz, B. Endometrial effects of a continuous percutaneous oestrogen/low-dose oral progestogen regimen for climacteric complaints. Maturitas 1987; 9: 63.
49Oosterbaan, HP, van Burren, AJHAM, Schram, JHN et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995; 21: 211.
50Wolfe, BM, Huff, MW. Effects of continuous lowdosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women. Metabolism 1995; 44: 410.
51Christiansen, C, Riis, BJ. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins and bleeding pattern. Br J Obstet Gynaecol 1990; 97: 1087–92.
52Christiansen, C, Riis, BJ. 17-β estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 4: 836.
53Fuleihan, G, Brown, EM, Curtis, K. Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism. Arch Mem Med 1992; 152: 1904.
54Riis, BJ, Hohansen, J, Christiansen, C. Continuous oestrogen-progestogen treatment and bone metabolism in postmenopausal women. Maturitas 1988; 10: 51.
55Bewtra, C, Kable, WT, Gallagher, JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med 1988; 32: 205–8.
56Farish, E, Fletcher, CD, Dagen, MM. Lipoprotein and apolipoprotein levels in post-menopausal women on continuous oestrogen/progestogen therapy. Br J Obstet Gynaecol 1989; 96: 358–64.
57Mattson, LA, Callberg, G, Samsioe, G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric patients. Maturitas 1982; 4: 95–102.
58Jensen, J, Riis, BJ, Strom, V, Christiansen, C. Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 1987; 97: 130.
59Hawthorne, RJS. The endometrial status of women on long-term continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1991; 98: 939.
60Cano, A, Fernandes, H, Serrano, S, Mahiques, P. Effects on continuous oestradiolmedroxyprogesterone administration on plasma lipids and lipoproteins. Maturitas 1991; 13: 35.
61Metka, M, Hanes, V, Heytmanek, G. Hormone replacement therapy: lipid responses to continuous combined oestrogen and progestogen vs. oestrogen monotherapy. Maturitas 1992; 15: 53.
62Suhonen, SP, Holmstrom, T, Alonen, HO, Lahteenmake, P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63: 36.
63Denke, MA. Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholestrolemic postmenopausal women. Am J Med 1995; 99: 29.
64Suvanto-Luukkonen, E, Sundstrom, H, Penttinen, J, Kauppila, A, Rutanen, EM. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995; 22: 255.
65Wollter-Svensson, LO, Stadberg, E, Andersson, K, Mattsson, LA, Odlind, V, Persson, I. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas 1995; 22: 199.
66Ainmelk, Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril 1996; 66: 962.
67Speroff, L, Rowan, J, Symons, J, Genant, H, Wilborn, W. The comparative effect on bone density, endometrium and lipids on continuous hormones as replacement therapy (CHART Study). JAMA 196; 276: 1397.
68Farish, E, Spowart, K, Barnes, JF, Fletcher, CD, Calder, A, Brown, A, Hart, DM. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions. Atherosclerosis 1996; 126: 77.
69Grey, A, Cundy, T, Evans, M, Reid, I. Medroxyprogesterone acetate enhances the spinal bone mineral density response to estrogen in late postmenopausal women. Clin Endocrinol 196; 44: 293–96.
70Kalogirou, D, Antoniou, G, Karakitsos, P, Kalogirou, O, Antoniou, D, Giannikos, L. A comparative study of the effects of an estradiolreleasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. Int J Fertil 1996; 41: 522–27.
71Tilly-Kiesi, M, Lappi, M, Puolakka, J, Luotola, H, Pyorala, T, Taskinen, MR. Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on lowdensity lipoprotein subclasses. Eur J Clin Invest 1996; 26: 1125.
72Eiken, P, Kolthoff, N, Nielsen, SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 19: 191.–193S.
73Ettinger, B, Li, D, Klein, R. Continuation of postmenopausal hormone replacement therapy; comparison of cyclic versus continuous combined schedules. Menopause 1996; 3: 185–89.
74Kupperman, HS. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Endocrinol Metab 1953; 13: 688–703.
75Henderson, BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161: 1859.
76Harlap, S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992; 166: 1986.
77Woodruff, JD, Pickar, JH for The Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213.
78The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996; 275: 370.
79Kurman, RJ, Kaminski, PF, Norris, HJ. The behavior of endometrial hyperplasia: a long term study of ‘untreated’ hyperplasia in 170 patients. Cancer 1985; 56: 403.
80Gelfand, MM, Ferenczy, A. A prospective 1-year study of estrogen and progestin in postmenopausal women. Obstet Gynecol 1989; 74: 398.
81Udoff, L, Langenberg, P, Adashi, EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 306.
82Bush, TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Kerenman, SG (ed) The menopause: biological and clinical consequences of ovarian failure; evolution and management. Serono Symposia, Norwell, Mass., 1990, p. 211.
83Stampfer, MJ, Colditz, GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47.
84Grady, D, Rubin, SM, Petitti, DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016.
85Shahar, E, Folsom, AR, Soloman, W et al. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996; 96: 1970.
86Gebara, OL, Mittleman, MA, Sutherland, P, Lipinska, I. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952.
87White, RE, Darkow, DJ, Lang, JL. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995; 77: 936.
88Stevenson, JL. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995; 49: 87.
89Tikkanen, MK, Kuusi, T, Nikkila, EA, Sipinen, S. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins: a review. Maturitas 1986; 8: 7.
90Newnham, HH. Oestrogens and atherosclerotic vascular disease: lipid factors. Ballieres Clin Endocrinol Metab 1993; 7: 61.
91Psaty, BM, Hackbert, SR, Atkins, D, Lemaitre, R et al. The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women. Arch Intern Med 1994; 154: 1333.
92Falkeborn, M, Persson, I, Adami, HO et al. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821.
93Grodstein, F, Stampfer, MJ, Manson, JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 336: 453.
94Andersson, K, Stadberg, E, Mattsson, LA, Rybo, G. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women-effects on lipid metabolism during 12 months of treatment. Int J Fertil 1996; 41: 476.
95Taskinen, MR, Puolakka, J, Pyorala, T, Luotola, H, Bjorn, M, Kaariainen, J, Lahdenpera, S, Ehnholm, C. Hormone replacement therapy lowers plasma Lp(a) concentrations. Arterioscler Thrombo Vase Biol 1996; 16: 1215–21.
96Lobo, RA. Effects of hormonal replacement on lipids and lipoproteins in post-menopausal women. J Clin Endocrinol Metab 1991; 73: 925–30.
97Udoff, L, Adashi, EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 869.
98Bass, KM, Newschaffer, CJ, Klag, MJ, Bush, TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153: 2209–16.
99Glueck, CJ, Lang, J, Hamer, T, Tracy, T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123: 59–64.
100Tikkanen, MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996; 23: 209–16.
101Stevenson, JC, Crook, D, Godsland, IF et al. Oral versus transdermal hormone replacement therapy. Int J Fertil 1993; 38(suppl): 30–35.
102Maher, VMG, Brown, BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229–235.
103Berglund, L. Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 1995; 6: 48–56.
104Meilhahn, EN, Kuller, LH, Matthews, KA, Stein, EA. Lp(a) concentrations in pre- and postmenopausal women over time: the Healthy Women Study. Circulation 1991; 84(suppl): 11–2170.
105Andersson, B, Mattson, LA, Hahn, L, Maria, P, Lapidus, L, Holm, G, Bengtsson, BA, Bjorntorp, P. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitis. J Clin Endocrinol Metab 1997; 82: 638–43.
106Wilcox, JG, Hwany, J, Hodis, HN, Sevanian, A, Stomczyk, FZ, Lobo, RA. Cardioprotective effects of individual conjugated equine estrogen through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 1997; 67: 57–62.
107Lindheim, SR, Presser, L, Ditkoff, E, Vijod, MA, Staczyk, FZ, Lobo, RA. A possible bimodal effect of estrogen in insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664–67.
108Wagner, JD, Martino, MA, Jayo, MJ, Anthony, MS, Clarkson, JB, Cefalu, WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 1996; 45: 1245–62.
109Daly, E, Vesky, MP, Hawkins, MM, Carson, JC, Gough, P, Marsh, S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80.
110Jick, H, Derby, LE, Myers, MW, Vasilakis, C, Newton, KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–87.
111Vanderbroucke, JP, Helmerhoest, FM. Risk of venous thrombosis with hormone replacement therapy. Lancet 1996; 348: 972.
112Simioni, P, Prandoni, P, Lensing, AW et al. The risk of recurrent venous thromboembolism in patients with an Arg-506- Glu mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399–403.
113Ericksen, EF, Kassem, M, Langdahl, B. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996; 19: 179.–183S.
114Pacifici, R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043–51.
115Whitehead, MI, Lobo, RA. Progestogen use in postmenopausal women. Consensus conference. Lancet; 2: 1243–44.
116The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 1996; 276: 1389–96.